CorMedix Inc. (CRMD) Q4 FY25 Earnings Call

2026 guidance is maintained, but DefendCast revenue is expected to be front-loaded before post-TDAPA price erosion.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-06
Length29 minutes
EPS$0.61
EPS consensus$0.86
Revenue$128.6M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All CRMD earnings ยท Back to CRMD overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.